CA2283975A1 - Combinaison de therapies pour le traitement de l'atherosclerose - Google Patents

Combinaison de therapies pour le traitement de l'atherosclerose Download PDF

Info

Publication number: CA2283975A1
Authority: CA; Canada
Prior art keywords: patient; aliquot; blood; cholesterol; administration
Prior art date: 1999-09-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002283975A

Other languages

English (en)

Inventor

David Elsley

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vasogen Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-28

Filing date

1999-09-28

Publication date

2001-03-28

1999-09-28 Application filed by Individual filed Critical Individual

1999-09-28 Priority to CA002283975A priority Critical patent/CA2283975A1/fr

2000-09-25 Priority to AU75002/00A priority patent/AU7500200A/en

2000-09-25 Priority to US10/089,362 priority patent/US7125897B1/en

2000-09-25 Priority to EP00963821A priority patent/EP1218017B1/fr

2000-09-25 Priority to DE60024114T priority patent/DE60024114T2/de

2000-09-25 Priority to PCT/CA2000/001112 priority patent/WO2001022976A2/fr

2000-09-25 Priority to AT00963821T priority patent/ATE309807T1/de

2000-09-25 Priority to JP2001526186A priority patent/JP2003510284A/ja

2000-09-25 Priority to CA002385327A priority patent/CA2385327A1/fr

2001-03-28 Publication of CA2283975A1 publication Critical patent/CA2283975A1/fr

Status Abandoned legal-status Critical Current

Links

201000001320 Atherosclerosis Diseases 0.000 title claims description 16
238000011282 treatment Methods 0.000 title description 21
238000002648 combination therapy Methods 0.000 title description 16
210000004369 blood Anatomy 0.000 claims abstract description 42
239000008280 blood Substances 0.000 claims abstract description 42
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 13
239000003529 anticholesteremic agent Substances 0.000 claims abstract description 13
230000001590 oxidative effect Effects 0.000 claims abstract description 11
208000037260 Atherosclerotic Plaque Diseases 0.000 claims abstract description 9
230000008646 thermal stress Effects 0.000 claims abstract description 8
238000011284 combination treatment Methods 0.000 claims abstract description 6
229940079593 drug Drugs 0.000 claims description 20
239000003814 drug Substances 0.000 claims description 20
150000002632 lipids Chemical class 0.000 claims description 17
210000002966 serum Anatomy 0.000 claims description 14
238000000034 method Methods 0.000 claims description 9
230000009467 reduction Effects 0.000 claims description 8
230000008569 process Effects 0.000 claims description 3
230000002708 enhancing effect Effects 0.000 claims description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 21
230000000694 effects Effects 0.000 description 8
239000007789 gas Substances 0.000 description 8
208000035150 Hypercholesterolemia Diseases 0.000 description 7
239000000203 mixture Substances 0.000 description 7
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 6
210000004204 blood vessel Anatomy 0.000 description 5
230000036760 body temperature Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
230000008021 deposition Effects 0.000 description 5
208000031226 Hyperlipidaemia Diseases 0.000 description 4
108010046315 IDL Lipoproteins Proteins 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
229960002855 simvastatin Drugs 0.000 description 4
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 3
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
229960005370 atorvastatin Drugs 0.000 description 3
229960005110 cerivastatin Drugs 0.000 description 3
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 3
229960003765 fluvastatin Drugs 0.000 description 3
229960004844 lovastatin Drugs 0.000 description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
229960002965 pravastatin Drugs 0.000 description 3
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
230000035882 stress Effects 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
108010069201 VLDL Cholesterol Proteins 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
235000018823 dietary intake Nutrition 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
229920000080 bile acid sequestrant Polymers 0.000 description 1
229940096699 bile acid sequestrants Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
229940107170 cholestyramine resin Drugs 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960002577 colestipol hydrochloride Drugs 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960001767 dextrothyroxine Drugs 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000008246 gaseous mixture Substances 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
150000002814 niacins Chemical class 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
-1 triglycerides Chemical class 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
229940045854 xanthinol niacinate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002283975A 1999-09-24 1999-09-28 Combinaison de therapies pour le traitement de l'atherosclerose Abandoned CA2283975A1 (fr)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
CA002283975A CA2283975A1 (fr)	1999-09-28	1999-09-28	Combinaison de therapies pour le traitement de l'atherosclerose
AU75002/00A AU7500200A (en)	1999-09-24	2000-09-25	Combined therapies for atherosclerosis treatment
US10/089,362 US7125897B1 (en)	1999-09-24	2000-09-25	Combined therapies for atherosclerosis treatment
EP00963821A EP1218017B1 (fr)	1999-09-24	2000-09-25	Polytherapie destinee au traitement de l'atherosclerose
DE60024114T DE60024114T2 (de)	1999-09-24	2000-09-25	Zusammensetzung zur behandlung von atherosklerose, welche ein statin und ex-vivo behandeltes blut enthält
PCT/CA2000/001112 WO2001022976A2 (fr)	1999-09-24	2000-09-25	Polytherapie destinee au traitement de l'atherosclerose
AT00963821T ATE309807T1 (de)	1999-09-24	2000-09-25	Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
JP2001526186A JP2003510284A (ja)	1999-09-24	2000-09-25	アテローム性動脈硬化症の処置のための併用療法
CA002385327A CA2385327A1 (fr)	1999-09-24	2000-09-25	Polytherapie destinee au traitement de l'atherosclerose

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002283975A CA2283975A1 (fr)	1999-09-28	1999-09-28	Combinaison de therapies pour le traitement de l'atherosclerose

Publications (1)

Publication Number	Publication Date
CA2283975A1 true CA2283975A1 (fr)	2001-03-28

Family

ID=4164236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002283975A Abandoned CA2283975A1 (fr)	1999-09-24	1999-09-28	Combinaison de therapies pour le traitement de l'atherosclerose

Country Status (1)

Country	Link
CA (1)	CA2283975A1 (fr)

1999
- 1999-09-28 CA CA002283975A patent/CA2283975A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2002-02-19	FZDC	Discontinued application reinstated
2002-10-24	FZDE	Discontinued

Publication	Publication Date	Title
KR100543413B1 (ko)	2006-01-20	전처리된 자가혈에 의한 울혈성 심부전증의 치료
NZ529243A (en)	2007-11-30	Use of polymethoxylated flavones for treating insulin resistance
WO1998001100A2 (fr)	1998-01-15	Methode de traitement de l'hypercholesterolemie familiale homozygote
LAYTON et al.	1991	A double‐blind, placebo‐controlled trial of topical PUVA in persistent palmoplantar pustulosis
AU768474B2 (en)	2003-12-11	Method for preventing or delaying catheter-based revascularization
Toyoda et al.	1997	Attenuation of ischemia-reperfusion injury in the rat neocortex by the hydroxyl radical scavenger nicaraven
US6264646B1 (en)	2001-07-24	Method for preventing and reversing atherosclerosis in mammals
AU768300B2 (en)	2003-12-04	Method for preventing and reversing atherosclerosis in mammals
CA2271190A1 (fr)	2000-11-06	Traitement ameliore des mammiferes avec du sang de mammiferes modifie
EP1218017B1 (fr)	2005-11-16	Polytherapie destinee au traitement de l'atherosclerose
CA2283975A1 (fr)	2001-03-28	Combinaison de therapies pour le traitement de l'atherosclerose
CA2283374A1 (fr)	2001-03-24	Therapies conjointes pour le traitement de l'arteriosclerose chez les mammiferes
WO2008100450A2 (fr)	2008-08-21	Effets thérapeutiques de bryostatines, de bryologues et d'autres substances apparentées sur l'altération de la mémoire induite par une ischémie/un accident vasculaire cérébral et une lésion cérébrale
US6800300B1 (en)	2004-10-05	Method for treating autoimmune and alloimmune diseases
John Chapman	2005	The potential role of HDL‐and LDL‐cholesterol modulation in atheromatous plaque development
CA2385327A1 (fr)	2001-04-05	Polytherapie destinee au traitement de l'atherosclerose
US7255880B2 (en)	2007-08-14	Treatment of endothelin-related disorders
US6140309A (en)	2000-10-31	Vasoactive effects and free radical generation by β-amyloid peptides
RU2007112409A (ru)	2008-12-10	Одновременный прием тигициклина и дигоксина
Qin et al.	2023	Heme oxygenase‐1 therapy attenuates muscle atrophy following global brachial plexus avulsion in juvenile rats
Iliakis et al.	2025	Towards the optimization of ozone therapy in knee osteoarthritis: Factors influencing treatment outcomes
Nakaya et al.	1994	Effect of a novel ACAT inhibitor, E5324, on serum lipids and lipoproteins in healthy volunteers
WO2002060461A1 (fr)	2002-08-08	Modulation de la barriere hemato-encephalique a l'aide de cellules sanguines autologues stressees
Shabana et al.	2019	Novel Agents for Treatment of Hyperlipidemia
US4885288A (en)	1989-12-05	Pharmaceutical compositions containing lysine acetylsalicylate